key: cord-1020854-pcptvzsg
authors: Fernandez Martinez, Alberto; Barajas Galindo, David; Ruiz Sanchez, Jorge
title: Management of hyponatraemia and hypernatraemia during the Covid-19 pandemic: a consensus statement of the Spanish Society for Endocrinology (Acqua Neuroendocrinology Group)
date: 2021-02-05
journal: Rev Endocr Metab Disord
DOI: 10.1007/s11154-021-09627-3
sha: 1a59c85d8a2767bcaef78b9a15b1cf92817c9afe
doc_id: 1020854
cord_uid: pcptvzsg

SARS-COV2 infection has swiftly become a pandemic disease of historic relevance and widely variable outcomes. This variable prognosis is related both to uneven damage, among others, to lungs, heart and kidneys, and to a multisystemic inflammatory reaction. All these factors are known to disrupt water balance and potentially induce hyponatraemia or hypernatraemia. Water balance disorders are known mortality and morbidity risk factors in several clinical scenarios and their proper management, though often complex and hazardous, can reduce mortality and length of hospitalization. Clinical uncertainty over COVID-19 outcome, the variety of organs involved in both the infection and water balance and difficulties in clinical examination due to risk of contagion might obstruct proper management of dysnatremic disorders. Thus, the Acqua Neuroendocrinology Group of the Spanish Society for Endocrinology (SEEN) has endeavoured to provide evidence and expert based recommendations on the management of hyponatraemia and hypernatraemia in COVID-19 patients.

20.5% and 3.7% had hyponatraemia and hypernatraemia, respectively [9] : both hyponatraemia and hypernatraemia were generally mild (130-134 mEq/l in 16.7%), severe hyponatraemia (<120 mEq/l) was found only in 0.4%. Multivariable logistic regression analysis showed that male sex and age > 70 years were independently associated with hyponatraemia at admission, whereas smoking, tachypnea and serum creatinine >1.5 mg/dl bore a positive, independent association with admission hypernatraemia. Finally, the HOPE registry revealed that hyponatraemia was an independent risk factor for mortality (OR 1.5, 95% CI 1.08-2.09; p = 0.016) and sepsis (OR 1.87, 95% CI 1.23-2.66; p < 0.001), as was the case also for hypernatraemia (Mortality OR 2.38, 95% CI 1. 18-4.78 ; p = 0.015. Sepsis OR 3.78, 95% CI. 1.98-7.22; p < 0.001) [9] .

Patients with chronic disorders of water homeostasis, such as diabetes insipidus (DI) or chronic hyponatraemia (CH) are prone to suffering exacerbations of water imbalance during COVID-19 pandemic, either due to the loss of follow-up in non-infected patients with DI or chronic hyponatraemia or the impact of SARS-COV2 infection on water homeostasis. Thus, the European Society of Endocrinology published expertbased recommendations on the management of diabetes insipidus and hyponatraemia in the time of COVID-19 [10] . However, published literature on COVID-19 and its related complications increases swiftly; meanwhile, further waves and incidence peaks are expected in the near future, and these recommendations were based on preliminary data on the disease and require further coverage on practical aspects of fluid and electrolyte balance in these patients.

According 1 Specific risks in patients with chronic hyponatraemia or diabetes insipidus and COVID-19

Mismanagement of water balance disorders during acute illness can worsen morbidity and mortality [11, 12] . Thus, adequate evidence-based treatment of CH or DI, as previously described in European and American Hyponatraemia Guidelines [13, 14] and in the European Society for Endocrinology statement on the management of these disorders during COVID-19 pandemic [10] , may improve outcomes, including risk of hospitalization and therefore SARS-COV2 exposure.

COVID-19, particularly in severe forms, can induce numerous electrolyte abnormalities that might be particularly severe in patients with chronic water balance abnormalities [2] . According to published literature, these are some of the most common alterations that might complicate the management of patients with wáter balance abnormalities and SARS-COV2 infection:

a. Complications linked to the COVID-19 pandemic that might worsen the outcome of patients with either DI or CH:

& COVID-19-related electrolyte abnormalities: hyponatraemia, hypernatraemia, hypokalemia, mixed alcalosis (respiratory alcalosis due to hyperventilation, metabolic alcalosis linked to hypovolaemia) & Loss of follow-up of CH or DI due to patient's and/or health care worker fear of contagion or work overload by the health care worker during COVID-19 outbreaks. & Difficulties accessing water due to psychosocial factors, such as social isolation during confinement and anxiety or depression linked to outbreaks, can be particularly harmful in CH and DI patients. Futhermore, water intake can activate mesolimbic reward circuits in the central nervous system, which could lead to psychogenic polydipsia in these patients and ultimately worsen water balance [15] .

b. DI-specific risks during COVID-19 pandemic:

& Loss of follow-up during the pandemic might lead to undetected hyponatraemia due to desmopressin overdose, particularly when administered through intranasal route [16] . SARS-COV2 infection might also increase antidiuresis. However, larger series with more in-depth description of volume status and serum and urine electrolytes are required. & During SARS-COV2 infection, extrarenal water loses might increase due to hyperpyrexia, hyperventilation and/or diarrhoea and cause hypernatraemia. This could worsen further if either the patient or health care workers do not ensure timely administration of desmopressin and monitorization of sodium levels take place regularly in patients with DI [17] . & Patients with central DI often suffer as well from adrenal insufficiency and hypothyroidism. Timely administration of thyroid hormones and glucocorticoid replacement is paramount, increasing the dose of glucocorticoids during intercurrent illnesses as described in clinical guidelines [18] . & Obesity is common in patients with central DI, particularly when other pituitary hormonal deficiencies or hypersecretion syndromes (i.e. Cushing's disease) are present. Obese patients suffer from worse COVID-19 related prognosis [19] , which highlights the need to reduce contagion risk in these patients. & Metabolic comorbidities in patients with central DI that could worsen COVID-19 prognosis: diabetes mellitus, hypertension, obstructive sleep apnea & Increased risk of thrombosis in DI due to hypernatraemia, which might worsen during SARS-COV2 infection, also associated with hypercoagulability, or in non-infected patients due to confinement, increased weight and lack of physical activity [20, 21] . Therefore, thromboprophylaxis should be systematically considered in COVID-19 patients with chronic DI.

c. Chronic hyponatraemia specific risks during COVID-19 pandemic:

a. Patients with chronic SIADH might suffer from decompensated hyponatraemia during COVID-19 infection due to thirst abnormalities during acute illness, lack of treatment adherence (i.e. tolvaptan, urea...) and/or treatment monitorization. b. Changes in volume status during intercurrent illness, i.e. hypovolaemia caused by vomiting or hyperpirexia with increased perspiration. Both tolvaptan and urea are licensed for use during euvolemic hyponatraemia due to SIADH, but patients with hyponatraemia might change volume status during acute illness.

iii. Chronic comorbidities common in patients with SIADH that might worsen COVID-19 prognosis: cancer, respiratory disorders, central nervous system disorders...

& Outpatient follow-up according to clinical guidelines [11] . If patients have preserved thirst sensation and are capable of regulating water intake and maintain treatment adherence, follow up could be performed through telemedicine (phone contact, videocalls...) with lab tests as required. & More stringent follow-up is indicated in the following scenarios: adipsic DI, neurocognitive impairment that concerns water intake or previous episodes of hyponatraemia due to desmopressin overdose.

b. COVID-19 in patients with chronic DI: Cooperation between health care workers dealing with COVID-19 and clinicians with expertise in water balance disorders is paramount in this scenario. Some aspects of DI treatment may vary according to COVID-19 severity [2, 22] and water balance status on presentation. & Patients with chronic SIADH should regularly receive clinical examination that includes the assessment of internal jugular vein pressure. These data are needed to appraise dose changes and even interruption of hyponatraemia pharmacotherapy (tolvaptan, urea...). Thus, patients with pharmacologically treated and chronic hyponatraemia are not fit for telemedicine follow-up appointments wherever this is problem is concerned. & Patients with chronic SIADH usually suffer from malnutrition as well due to common precipitating factors (multimorbidity). Malnutrition is an absolute contraindication for water restriction as a treatment for hyponatraemia, as water-restricted dieting might worsen nutritional outcomes. In patients with SIADH and without malnutrition, confinement and/or loss of social interaction might also hinder adherence to water restriction; in this situation pharmacotherapy for hyponatraemia should also be considered according to stablished guidelines [9, 10] . & Hyponatraemia, whatever the underlying causes, represents a risk factor for mortality and increased length of hospitalization. Therefore, hyponatraemia should be identified and treated accordingly in COVID-19 patients [12] & Diagnosis of new-onset hyponatraemia in COVID-19 patients should initially include plasma and urine osmolality, sodium and potassium and clinical assessment of volume status. Further etiological tests should be guided by the patient's underlying conditions and risk factors, volume status and evolution. COVID-19 might be associated with multiple underlying disorders that might precipitate or aggravate hyponatraemia (Fig. 2) . Among those etiologies, endocrinological assessment should include free thyroxine and thyroid stimulating hormone measurement, as COVID-19 can be associated with thyroid dysfunction [24] , as well as diagnostic tests for adrenal insufficiency (9 am cortisol and/or synacthen test). Adrenal failure might be elicited by direct SARS-COV2 infiltration of adrenal cells or by dexamethasone-induced adrenal suprression [18, 25] . & Patients suffering from COVID-19 should not be waterrestricted in order to treat hyponatraemia. SARS-COV2 infection is often associated with malnutrition, increased perspiration and hyperventilation, and these factors may aggravate the adverse effects of water restriction. [2, 3, 23] . & Monitoring of COVID-19 patients with hyponatraemia should include daily measurements of plasma and urine sodium, potassium, creatinine and osmolality and clinical assessment of volume status (measurement of internal jugular vein pressure, intraocular pressure...). More intensive monitoring could be required in patients with severe hyponatraemia or those with rapidly evolving hyponatraemia.

-Hyponatraemia pharmacotherapy during COVID-19:

i. Indications for hyponatraemia pharmacotherapy in COVID-19 patients: euvolemic hyponatraemia with plasma sodium >120 mEq/l, after excluding adrenal insufficiency and hypothyroidism. Most COVID-19 patients will not be suitable candidates for water restriction as a treatment for hyponatraemia due to malnutrition, loss of thirst and increased extraurinary water loss. These patients should therefore be treated with tolvaptan or urea according to clinical guidelines [13, 14] . ii. Treatment interactions between hyponatraemia and SARS-COV2 pharmacotherapy: described in Table 1 and for each drug in its specific section. patients, who also display high activity of the reninangiotensin-aldosterone axis [3, 30] .

Hypernatraemia is a common laboratory abnormality in COVID-19 patients, found in 3,7% of patients hospitalised due to COVID-19 in the HOPE registry [9] . Similarly to hyponatraemia, increased plasma sodium levels are an adverse prognostic factor in non-COVID patients although this awaits confirmation in COVID-19 series. Hypernatraemia in COVID-19 develops due to an inbalance between increased water loss (hyperpyrexia, diarrhoea, vomiting, polyuria due to hyperglycemia or acute kidney injury...) and decreased water supply (anorexia with adipsia, altered consciousness, insufficient parenteral replacement...) [31, 32] . Diabetes insipidus as a direct consequence of SARS-COV2 has not been pathophysiologically described so far. Therefore, while awaiting descriptive studies of hypernatraemia in this population, it could be safely assumed that COVID-19 patients with hypernatraemia mostly suffer increased extrarenal water loss.

Treatment of hypernatraemia in COVID-19 patients is similar to that described in the general population, based on parenteral fluid replacement [31] .

General recommendations:

& Thrombosis prevention: hypernatraemia and SARS-COV2 infection are both independent thrombosis risk factors. If no contraindication is found, low weight heparine profilaxis should be initiated on admission. & Plasma and urine sodium measurement every 12-24 h & Objective: reduction of sodium levels <10 mEq/l every 24 h to reduce the risk of cerebral edema & Severe hypernatraemia with loss of consciousness -Dextrose 5% serum at 1.35 ml/kg-hour -If there is clinical hypovolaemia, administer isotonic serum (saline serum 0,9% or Ringer) parallel to dextrose at 30 ml/kg/day to increase effective circulating volume. Patients with increased risk of cerebral edema (liver failure, heart failure) may receive instead saline serum 0,45% at 30 ml/kg-day.

Data availability not applicable.

Conflict of interest none relevant to the article.

Ethics approval not applicable.

WHO Coronavirus Disease

Severe Covid-19

Extrapulmonary manifestations of COVID-19

An unusual case of severe acute hyponatraemia in patient with COVID-19 infection

The many faces of COVID-19: atypical presentation of COVID-19 in a patient with Crohn's disease with acute diarrhea leading to severe hypovolemic Hyponatraemia-a case report

Atypical presentation of COVID-19 in an older adult: lethargy and vomiting from severe hypovolemic Hyponatraemia

Fluid replacement versus fluid restriction in COVID-19 associated Hyponatraemia. Cureus

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Prognostic Impact of Hyponatraemia and Hypernatraemia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front Endocrinol

ENDOCRINOLOGY IN THE TIME OF COVID-19: management of diabetes insipidus and hyponatraemia

Society for Endocrinology Clinical Guidance: Inpatient Management of Cranial Diabetes Insipidus

Mortality rates are lower in SIAD, than in hypervolaemic or hypovolaemic hyponatraemia: Results of a prospective observational study

Hyponatraemia treatment guidelines 2007: expert panel recommendations

Clinical practice guideline on diagnosis and treatment of Hyponatraemia

Of mice and men-the physiology, psychology, and pathology of Overhydration

Comparison of incidence of hyponatraemia between intranasal and oral desmopressin in patients with central diabetes insipidus

Clinical guidelines for management of diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion after pituitary surgery

ENDOCRINOLOGY IN THE TIME OF COVID-19: management of adrenal insufficiency

COVID-19 and Obesity: Dangerous Liaisons

COVID-19 and its implications for thrombosis and anticoagulation

Adipsic diabetes insipidus and venous thromboembolism (VTE): recommendations for addressing its hypercoagulability

Mild or Moderate Covid-19

Nutrition in critically ill patients with COVID-19: challenges and special considerations

Impact of COVID-19 on the thyroid gland: an update

What we have to know about corticosteroids use during Sars-Cov-2 infection

The use of an oral salt load followed by furosemide in the treatment of euvolemic SIADH-induced hyponatraemia

The Effect of the Dose of Isotonic Saline on the Correction of Serum Sodium in the Treatment of Hypovolemic Hyponatremia

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics Rev Endocr Metab Disord of tolvaptan, a non-peptide AVP antagonist in healthy subjects

Disease-drugdrug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease

Diagnosis and treatment of hypernatraemia

Hypertonicity: clinical entities, manifestations and treatment

Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM)

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations